Compare Invesco S&P 500 Low Volatility ETF (SPLV) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Invesco S&P 500 Low Volatility ETF vs Tango Therapeutics Inc. — how do they compare? Invesco S&P 500 Low Volatility ETF trades at $73.21 (market cap $7.06B), while Tango Therapeutics Inc. trades at $22.23 (market cap $3.75B). The key difference: Invesco S&P 500 Low Volatility ETF is the larger of the two by market cap, and Tango Therapeutics Inc. is trading nearer its 52-week high, Invesco S&P 500 Low Volatility ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Invesco S&P 500 Low Volatility ETF for 124 Days and Tango Therapeutics Inc. for 0 Days on average.
| SPLV | TNGX | |
|---|---|---|
Market Cap | $7.06B | $3.75B |
Volume | 1,461,921 | 9,619,106 |
52-Week High | $77.97 | $32.90 |
52-Week Low | $70.30 | $7.50 |
Typical Hold Time | 124 Days | 0 Days |
Sector | — | Health |
Enterprise Value | — | $2.77B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SPLV trades at $72.98, up 0.26% with a bullish technical signal from moving averages, though oscillators show neutral momentum. The ETF's sector allocation to utilities and real estate has lagged the broader market, returning 5% versus the S&P 500's 17% year-to-date. Recent dividend payments of $0.14 provide income stability amid market volatility.
Outlook remains cautious as growth-adjusted valuations appear stretched at 19.5x P/E. Risks include sector concentration and macroeconomic pressures, but SPLV offers defensive exposure during market uncertainty. The neutral analyst stance reflects balanced near-term prospects between stability benefits and performance headwinds.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Invesco S&P 500 Low Volatility ETF
The fund generally will invest at least 90% of its total assets in the securities that comprise the underlying index. Strictly in accordance with its guidelines and mandated procedures, S&P Dow Jones Indices LLC (the "index Provider") compiles, maintains and calculates the underlying index, which is designed to measure the performance of the 100 least volatile constituents of the S&P 500 ® Index over the past 12 months as determined by the index Provider.
Read more on SPLV →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
